Efficacy and safety of anti-hyperglycaemic drugs in patients with non-alcoholic fatty liver disease with or without diabetes: an updated systematic review of randomized controlled trials.
CONCLUSION: - RCT evidence supports the efficacy of some anti-hyperglycaemic agents (especially pioglitazone) in patients with NAFLD or NASH, though weight gain with pioglitazone may warrant caution. Further well-designed RCTs are needed to better characterize the efficacy and safety of monotherapy and combination therapy with anti-hyperglycaemic agents in patients with NAFLD.
PMID: 31923578 [PubMed - as supplied by publisher]
Source: Diabetes and Metabolism - Category: Endocrinology Authors: Mantovani A, Byrne CD, Scorletti E, Mantzoros CS, Targher G Tags: Diabetes Metab Source Type: research
More News: Actos | Alcoholism | Databases & Libraries | Diabetes | Diabetes Mellitus | Diabetes Type 2 | Endocrinology | Fatty Liver Disease (FLD) | Fortamet | Insulin | Liver | Liver Disease | Metformin | Non-alcoholic Fatty Liver Diseases (NAFLD) | Sodium | Study | Urology & Nephrology | Victoza
MedWorm Privacy Policy
Disclaimer
Copyright © MedWorm 2006-2024